Eli Lilly and Company has announced plans to build a $6.5 billion next-generation active pharmaceutical ingredient (API) manufacturing facility at … Continue reading Eli Lilly’s Next-gen $6.5B API and GLP-1 Orforglipron Facility, Houston, Texas, USA